Apogee Therapeutics (APGE) Stock Price, News & Analysis

Company Overview

Apogee Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic medicines for inflammatory and immunologic diseases. The company’s approach centers on designing therapies with extended half-lives and other potentially differentiated properties intended to improve treatment durability and patient convenience.

Apogee’s pipeline includes APG777, an extended-half-life monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in allergic inflammation. The company is evaluating APG777 in conditions including atopic dermatitis and asthma. Apogee is also advancing additional discovery and clinical programs directed at important targets associated with inflammatory and immunologic disorders.

Founded in 2022, Apogee is headquartered in the United States and conducts research and clinical development activities through collaborations and operations supporting its biologics pipeline. Michael Henderson serves as the company’s chief executive officer. Apogee Therapeutics’ common stock trades on the Nasdaq under the symbol APGE.

Key Stats

• Today's Range: $135.07 to $135.07
• 50-Day Range: $133.82 to $135.10
• 52-Week Range: $35.39 to $135.09
• Volume: N/A
• Average Volume: 1.39 million shs
• Market Capitalization: $8.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $126.77
• Consensus Rating: Hold

Apogee Therapeutics Stock Analysis - MarketRank™

Apogee Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 808th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Apogee Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.16, and is based on 1 strong buy rating, 2 buy ratings, 15 hold ratings, and 1 sell rating.

Downside Risk

Apogee Therapeutics has a consensus price target of $126.77, representing about 6.1% downside from its current price of $135.07.

Amount of Analyst Coverage

Apogee Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Apogee Therapeutics are expected to decrease in the coming year, from ($4.47) to ($5.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Apogee Therapeutics is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Apogee Therapeutics is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Apogee Therapeutics has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.93% of the float of Apogee Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Apogee Therapeutics has a short interest ratio ("days to cover") of 3.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apogee Therapeutics has recently decreased by 1.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apogee Therapeutics does not currently pay a dividend.

Dividend Growth

Apogee Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for APGE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Apogee Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,244,445.00 in company stock.

Percentage Held by Insiders

24.30% of the stock of Apogee Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:APGE
• CIK: 1974640
• Web: www.apogeetherapeutics.com
• Phone: 650-394-5230
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Apogee Therapeutics: $126.77
• High Price Target: $160.00
• Low Price Target: $89.00
• Potential Upside/Downside: -6.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.16
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$255.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.88%
• Return on Assets: -28.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.44
• Quick Ratio: 26.44

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.21 per share
• Price / Book: 7.03

Miscellaneous

• Outstanding Shares: 62,201,000
• Free Float: 47,086,000
• Market Cap: $8.40 billion
• Optionable: Optionable
• Beta: 0.33